Type 2 Diabetes Mellitus (T2DM) · Phase 2 Trial

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov · September 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 2 dose-response study of maridebart cafraglutide versus placebo in 409 adults with type 2 diabetes, with HbA1c change at 24 weeks as the primary outcome. No results are posted in this registry record, so no efficacy or safety findings can be assessed.

What was studied

Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Type 2 Diabetes Mellitus (T2DM); age from 18 Years. Intervention: Maridebart Cafraglutide. Compared with: Placebo — Placebo Comparator. n = 409. 96 sites across 14 countries.

Key findings

Safety

Registry record only; no results, efficacy data, safety data, or outcome comparisons are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a Phase 2 trial registry record with no posted results; it describes a planned or ongoing study design and enrollment, not efficacy or safety outcomes.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (assessed at Baseline to Week 24)

DesignPhase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose

PopulationType 2 Diabetes Mellitus (T2DM); age from 18 Years

Sample size409

InterventionMaridebart Cafraglutide

ComparatorPlacebo — Placebo Comparator

Setting96 sites across 14 countries

Reported figures

Quoted from the source exactly as published.

Sample size409

PhasePhase 2

Primary endpointChange from baseline to week 24 in hemoglobin A1c (HbA1c)

Follow-up duration24 weeks

Caveats

Registry record only; no results, efficacy data, safety data, or outcome comparisons are reported.
Blinding status, randomization method, allocation concealment, and other methodological details are not stated.
Dose-response relationship and comparative effect versus placebo cannot be assessed without posted results.
Recruitment status is 'ACTIVE_NOT_RECRUITING,' indicating the trial is ongoing; results may not yet be available.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2, interventional, randomized comparison to placebo stated implicitly.

Directness

strong

Primary outcome is HbA1c change, a direct measure of glucose control in T2DM.

Consistency

insufficient

Registry record only; no results posted to assess consistency with other trials.

Risk of bias

insufficient

Blinding status, allocation concealment, and other methodological details not stated.

Sample adequacy

moderate

409 participants enrolled; Phase 2 context limits statistical power for definitive claims.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06660173). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 409 participants (ACTUAL). Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: DRUG: Maridebart Cafraglutide; DRUG: Placebo. Primary outcome measures: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) , Baseline to Week 24. Brief summary: The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT06660173AmgenType 2 Diabetes Mellitus (T2DM)